

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 03/30/2003

On March 28, 2003, [redacted] was interviewed at [redacted] place of employment, [redacted] UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES (USAMRIID), Fort Detrick, Maryland, telephone [redacted]. After being advised of the identities of the Agents and the purpose of the interview, [redacted] provided the following information:

b6
b7C

The usual contingent of people from the [redacted] [redacted] were likely in attendance at [redacted]. [redacted] listed the following individuals as possible [redacted] BRUCE IVINS, [redacted]. In addition, individuals from [redacted] may have been in attendance. [redacted] did not recall [redacted]. Pictures may have been taken during the event.

[redacted] did not interact with [redacted] during [redacted] tenure at USAMRIID and did not recall hearing [redacted] name mentioned. [redacted] did not even recognize [redacted] picture when shown in the [redacted]. [redacted] did not have access to [redacted] at USAMRIID.

[redacted] has conducted research strictly in Building [redacted] suites [redacted]. Investigations using virulent strains have been performed by [redacted] in Suites [redacted] areas). [redacted] in addition to work with attenuated strains (bacteria that do not cause disease), have been conducted in Suite [redacted] area). [redacted] as [redacted] has not been properly [redacted] has not witnessed the aerosol challenges conducted in Building [redacted].

b6
b7C
b2
b7E

Suites [redacted] have been shared with other individuals in the [redacted] to include the following: [redacted]

b6
b7C
b2
b7E

[redacted] BRUCE IVINS, [redacted]

091 01.302 SUB 302 - 3538

Investigation on 03/28/2003 at Fort Detrick, Maryland

b6
b7C

File # 279A-WF-222936-USAMRIID 279A-BA-C101392 Date dictated 03/30/2003

by SA [redacted]

279A-WF-222936-USAMRIID

b6
b7C

Continuation of FD-302 of [REDACTED]

, On 03/28/2003 , Page 2

[REDACTED]
[REDACTED] may have been authorized to access [REDACTED] but they did not go into these areas. Since the Fall of 2001, access to Suites B3 and B4 has become more restricted. There is a large lyophilizer in the hallway outside of Suite [REDACTED] in Building 1425. Everyone in the area would notice if it was in use. A lyophilizer is not present in either Suites [REDACTED] or [REDACTED] nor in [REDACTED]

b6
b7C
b2
b7F

[REDACTED] described [REDACTED]
[REDACTED]
[REDACTED] If contamination were present in [REDACTED] likely sites would be handles to doors and incubators, in addition to controls of equipment, where there is a high frequency of work conducted with organisms. [REDACTED] does not wear gloves in the change room or offices.

[REDACTED] was given [REDACTED]
[REDACTED] did not handle the envelopes or letters containing the evidentiary *Bacillus anthracis* (B.a.) materials. The letters arrived at USAMRIID [REDACTED]
[REDACTED]
[REDACTED] did not witness the handling of the letters, but believes that BRUCE IVINS [REDACTED] worked on a letter in Building 1425, Suite B3 [REDACTED] witnessed IVINS [REDACTED] working with the letter in this area. A chain of custody exists, documenting work conducted on the evidentiary material in Suite B3 [REDACTED] understands from BRUCE IVINS [REDACTED] initiated the cell count conducted in Suite B3.

The conflicting stories over the handling of the Daschle letter are due partly to contamination issues at USAMRIID. [REDACTED] characterized the issue as a problem of perception. The Division feels crucified for contaminating an area. In addition, the questioning of work place practices has been viewed as an attack on personal pride. [REDACTED] believes that the contamination issues have been overly hyped. Improper packaging initially of the Daschle letter may have led to the contamination.

b6
b7C

279A-WF-222936-USAMRIID

Continuation of FD-302 of [REDACTED]

, On 03/28/2003 , Page 3

b6
b7C

[REDACTED] received [REDACTED] stock of B.a. Ames from BRUCE IVINS. IVINS went back to the original B.a. Ames slant and generated a new stock in order to keep the pathogen as close to the host as possible. IVINS provided his Ames strain to [REDACTED] in the following manner: He retrieved his stock from the freezer, took out a loop and plated it on agar. He then gave the plate to [REDACTED]. In addition to the B.a. Ames stock, [REDACTED] recalled obtaining an spore preparation from IVINS [REDACTED]. This material was generated from IVINS' stock of Ames.

To maintain uniformity of lineage among the laboratory groups working together, [REDACTED]

[REDACTED] everyone already had their own Ames stocks. Investigators in the Bacteriology Division used IVINS' Ames stock. [REDACTED] was not sure of the origin of the Ames used by [REDACTED] derived from the original slant. [REDACTED] various B.a. strains [REDACTED] but not Ames.

[REDACTED] does not store much in the way of 'true' Ames stocks or spore preparations. It would be fairly obvious if vials were missing. However, someone could take a loop out without notice. With the small volumes of Ames that [REDACTED] stores, if an appreciable volume was gone, [REDACTED] would notice. [REDACTED] stores numerous stocks of Ames variants. These materials are visually distinct from wild type Ames. 'Normal' Ames appears pale gray, with medusa-like colonies, when plated and is not hemolytic. With aging, the culture becomes grainy and blebs appear. Ames mutants appear yellow in color and display hemolytic activity. If a person did not know better, he might mistake the mutant material as not anthrax.

[REDACTED] has never had a reason to generate a large amount of B.a. Ames spores. [REDACTED]

b6
b7C
b7F

279A-WF-222936-USAMRIID

Continuation of FD-302 of [REDACTED], On 03/28/2003, Page 4

[REDACTED] submitted Ames samples remaining from this study to the FBI repository. [REDACTED] recombinant anthrax vaccine study, [REDACTED] was conducted using B.a. [REDACTED]

b6
b7C

[REDACTED] diagramed the experimental procedure for the Agents. A copy of this diagram is attached and the original is maintained in a 1A envelop (FD-340). [REDACTED]

b6
b7C
b7F

[REDACTED] The vials containing Ames, which still remained after this study, were submitted to the FBI repository. [REDACTED]

[REDACTED] typically used [REDACTED]

The investigators at USAMRIID purchase their own supplies. [REDACTED]

b6
b7C

[REDACTED] Large plastic bins are not of practical use for [REDACTED] work in the laboratory. [REDACTED] may use these types of containers for the storage of files at home. Small plastic boxes with gaskets are used for materials that require airtight storage. Steel containers and Styrofoam coolers are used for transport of materials between buildings. [REDACTED] did not recall observing the use of large plastic bins in Building [REDACTED] and was not sure if these containers were used in Building [REDACTED]

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 04/21/2003

On 04/15/2003 SA [] accompanied []
[] to [] laboratory located in room [] of building
[] of the U.S. ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS
DISEASES (USAMRIID) to view [] laboratory notebooks.

b6
b7C

In a 3-ring binder labeled []
[] SA [] found reference to:

b6
b7C
b7F

A *Bacillus anthracis* Ames strain (Ames) spore preparation
from [] produced via []
was [] sporulated at a concentration of []
[] per milliliter (ml) of solution.

A [] challenge using Ames spores on
[]

An experiment on [] using [] purification
of *Bacillus anthracis* Sterne strain in practice for the
purification of *Bacillus anthracis* Vollum and Ames strains.

A [] protocol on the purification of spores via a
Renografin density gradient.

A [] Ames spore preparation made via []
sporulation plates.

[] and [] Ames spore preparations made
for []
[]

An Ames spore preparation, harvested during []
[] Final
concentration []

Ames spore preparation for [] harvested during
[] purified via [] and
[] and combined on [] Final concentration []
[]

b2
b7E

Investigation on 04/15/2003 at Fort Detrick, Maryland

File # 279A-WF-222936-USAMRIID, 279A-BA-C101392 Date dictated 04/21/2003

by SA []

128

b6
b7C

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 04/15/2003

[redacted] date of birth [redacted] Social
Security Account Number (SSAN) [redacted]

b6
b7C

[redacted] work
telephone [redacted] was interviewed at [redacted] place of
employment. After being advised of the identity of the
interviewing agents and the nature of the interview, [redacted]
provided the following information:

[redacted] advised that [redacted] conducted [redacted]

As part of his [redacted] employment, [redacted] worked at the
United States Army Medical Research Institute for Infectious
Diseases (USAMRIID) under [redacted]
[redacted] advised that [redacted] worked in the laboratory of
[redacted] at USAMRIID. [redacted] was introduced to
[redacted] at USAMRIID, and in the [redacted]
was brought into the [redacted]
eventually given access to the Biosafety Level [redacted] containment
suite located in Building [redacted] at Fort Detrick. [redacted] was trained
in suite access by [redacted]

b6
b7C

[redacted] research at [redacted] involved the development of a
[redacted]
facilities in Building [redacted] at USAMRIID were used by [redacted] to
[redacted]

b6
b7C
b2
b7F

Investigation on 04/15/2003 at [redacted]
279A-WF-222936-USAMRIID - 138
File # 279A-WF-222936-302 279A-BA-C101392

Date dictated 04/15/2003

by [redacted]

b2
b7E

b6
b7C

279A-WF-222936

279A-WF-C101392

Continuation of FD-302 of [REDACTED], On 04/15/2003, Page 2

b6
b7C
b7F

[REDACTED]

The [REDACTED] research team working with [REDACTED] at USAMRIID consisted of [REDACTED]

[REDACTED]

[REDACTED] advised that for [REDACTED] using Ba Ames Strain, [REDACTED] did not grow [REDACTED] spores. Initially [REDACTED] obtained a small amount of Ba Ames from [REDACTED] [REDACTED] needed more highly purified Ames Strain spores for [REDACTED] research. [REDACTED] advised that the primary source of BA Ames used in [REDACTED] research was BRUCE IVINS' research group. IVINS provided [REDACTED] [REDACTED] prepared spores contained in a [REDACTED]

[REDACTED] advised that [REDACTED] would take a small sample of spores from the original [REDACTED]

[REDACTED]

[REDACTED] stated that [REDACTED] kept the [REDACTED] bottle containing [REDACTED] in a safety container which was sealed by a rubber gasket. [REDACTED] stored the [REDACTED] in a drawer in the walk-in refrigerator located on the [REDACTED] of Building [REDACTED]

[REDACTED] advised that after the renovation of Building 1412 was complete in the year 2000 or 2001, [REDACTED] kept some [REDACTED] containing deposited Ba Spores in the walk-in refrigerator located on the [REDACTED] of Building [REDACTED] [REDACTED] advised that before the anthrax mailings some researchers kept their items in the

b6
b7C
b2
b7F

279A-WF-222936

279A-WF-C101392

Continuation of FD-302 of _____, On 04/15/2003, Page 3

b6
b7C

refrigerators using "inappropriate" containers such as cardboard boxes. [] stated that after the mailings administrative procedures were tightened and the use of cardboard boxes in the refrigerators discontinued.

[] stated that when [] work at USAMRIID was concluded, [] turned over the remainder of [] Ba Ames Strain [] advised that there is written documentation regarding the transfer of the Ba to [] advised that [] never transferred any Ba to any other researcher, nor did [] take any Ba out of Building 1412.

b6
b7C

[] advised that [] did not know what media was used to grow the Ba Ames Strain which [] was given by IVINS' group to conduct [] research. [] stated that [] was not immediately aware of the concentration of spores in [] but believed that this was documented. [] stated that [] notebooks are still located in the "hot suite" in Building []

[] advised that in []

After the letter containing B.a. spores was recovered from the office of SENATOR THOMAS DASCHLE in September 2001, []

b6
b7C
b7F

[] has not been asked to participate in any of the forensic research related to the anthrax mailings.

[] advised that [] left USAMRIID and went to work at []

[] stated that [] last name unknown (LNU) worked at USAMRIID []

b6
b7C

[] advised that everyone [] observed conducting research at USAMRIID practiced good safety procedures in the hot suites. [] advised that [] would have liked USAMRIID to have

279A-WF-222936

279A-WF-C101392

Continuation of FD-302 of [REDACTED], On 04/15/2003, Page 4

b6
b7C

had better access controls regarding the storage of bacteria and other agents.

[REDACTED] recalled [REDACTED] working in the laboratory in [REDACTED] advised that [REDACTED] also recalled [REDACTED] from the laboratory. [REDACTED] stated that [REDACTED]

b6
b7C

[REDACTED] stated that if one wanted to know what was going on at USAMRIID, they should talk to [REDACTED] employees.

b6
b7C

[REDACTED] advised that [REDACTED] did not know [REDACTED] did remember [REDACTED] telling [REDACTED] about the [REDACTED] working at USAMRIID.

[REDACTED] advised that [REDACTED] telephone [REDACTED] may be able to provide contact information for [REDACTED]

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 05/28/2003

[redacted]
[redacted]
[redacted] office phone number, [redacted] and
cell number [redacted] date of birth [redacted] Social
Security Account Number [redacted] home address [redacted]
[redacted] was interviewed at [redacted] place of
employment. After being advised of the identity of the interviewing
agents and the purpose of the interview, [redacted] provided the
following information:

b6
b7C

[redacted] received a [redacted]
[redacted]
[redacted] A curriculum vitae provided by [redacted] is attached.

[redacted] currently is the [redacted] which is
involved in the [redacted]

[redacted] the United
States Army Medical Institute of Infectious Diseases (USAMRIID)
from [redacted]
USAMRIID from [redacted]
[redacted]

[redacted] continuing education includes but is not limited
to the following: [redacted]
[redacted]

Investigation on 05/28/2003 at Frederick, MD
279A-WF-222936-POI 279A-BA-C101392
File # 279A-WF-222936-302 279A-WF-222936-USAMRIID dictated 05/28/2003
by [redacted] Postal Inspector: [redacted]
[redacted] FBI

b6
b7C

140
copy
Stamped &
initialed in
302 subfile
Serial
3838

279A-WF-222936-302 279A-WF-222936-USAMRIID

Continuation of FD-302 of [redacted], On 05/28/2003, Page 2

b6
b7C

[redacted] experience includes [redacted]
[redacted] at USAMRIID. [redacted]
[redacted]

[redacted] has an
[redacted] work, experience, professional organization membership,
[redacted] which is included in a 1A envelope with
this report.

[redacted] stated that [redacted]
[redacted]
work included vaccine/antibiotics studies and [redacted]
[redacted] In these studies, [redacted]
worked with a [redacted]
[redacted]

[redacted] indicated that USAMRIID [redacted]
[redacted]
involved in work on molecular biology of Bacillus anthracis (B.a.).
[redacted] stated that [redacted] was aware of the utilization of wet spray
while experimenting with (B.a.). [redacted] stated that other
individuals, who were involved in molecular work with Ba, included
[redacted] BRUCE IVINS [redacted]
[redacted] was not
aware of any work conducted at USAMRIID utilizing lyophilizers for
drying (B.a.).

[redacted]
[redacted] related that [redacted]
was not aware of any other disgruntle employee's at USAMRIID.

[redacted] related that [redacted] has the expertise to
weaponize B.a., but [redacted] had not been working in the laboratory

279A-WF-222936-302 279A-WF-222936-USAMRIID

Continuation of FD-302 of [REDACTED], On 05/28/2003, Page 3

b6
b7C

[REDACTED] at USAMRIID during the time [REDACTED] used [REDACTED]

[REDACTED]
These studies often dealt with the weaponization of (B.a.).
[REDACTED]

[REDACTED] stated that the Ames strain of B.a. was stored in Suite [REDACTED] in building 1425 at USAMRIID, and that [REDACTED] worked in [REDACTED]

b6
b7C
b2
b7F

[REDACTED] related that the only security or access problem that [REDACTED] was aware of at USAMRIID was an employee that gained access to a hot suite using another employee's access badge. [REDACTED] could not recall who the employees were, but recalled that the individual/individuals involved in the incident had authorization to be in the hot suites, but forgot his/her access badge. [REDACTED] could not recall any other situation involving improper access to the hot suites.

b6
b7C

[REDACTED] was questioned as to the physical security at USAMRIID and as to any weakness in security that would allow someone to take any biological or chemical agents from the base. [REDACTED] stated that the base had tight controls in place and was partially due to Congress's implementation of the Select Agent Rule prior 1997, whereby controls were implemented to safe guard agents that were to be removed and transferred from facility to facility. These controls included the review and approval of any select agent transfer by the Deputy Commander and the head of security of USAMRIID, [REDACTED] stated that the recently adopted Patriot Act also tightened controls on the transfer of select agents.

[REDACTED] opined that the Ames strain used in the Anthrax mailings could have come from USAMRIID, but [REDACTED] believed that it would not have been taken from USAMRIID in a dry form. [REDACTED] advised that [REDACTED] believes a person would have had to have taken a small amount of B.a. Ames, and would have had to grow the B.a. on their own. [REDACTED] said that they could grow it using a blood agar and washing it with water three to five times. [REDACTED] related in order to achieve a high quality the spores could be washed up to fifteen times. [REDACTED] stated that in order to dry B.a., solvent methods could

279A-WF-222936-302 279A-WF-222936-USAMRIID

b6
b7c

Continuation of FD-302 of [REDACTED], On 05/28/2003, Page 4

be utilized rather than another drying process. In this way, the B.a. would not have to be milled to achieve a powder form. [REDACTED] related that as soon as B.a. is dried it is a highly dangerous substance.

[REDACTED] theorized that it is possible for one person to be responsible for the mailings but [REDACTED] would not discount that the mailings were State sponsored terrorism. [REDACTED] then related that [REDACTED]

[REDACTED] advised that Clorox would be sprayed on to decontaminate Class I and Class II bio-safety cabinets. Paraformaldehyde fumigation was also part of the Standard Operating Procedure (SOP) at USAMRIID in the decontamination process. [REDACTED] stated that usage of glutaraldehyde, as a decontamination agent, was limited and was not utilized in the suites as it was too dangerous. [REDACTED] said that [REDACTED] the decontamination efforts at USAMRIID.

[REDACTED] saw [REDACTED] had not known [REDACTED] very well at USAMRIID. [REDACTED] stated that [REDACTED]

[REDACTED]

[REDACTED] was questioned as to [REDACTED] involvement with [REDACTED] recalled that [REDACTED] could not recall any other specific information regarding [REDACTED]

[REDACTED] requested to end the interview before questioned had been concluded, as [REDACTED] needed to respond to some incoming phone

279A-WF-222936-302 279A-WF-222936-USAMRIID

Continuation of FD-302 of , On 05/28/2003, Page 5

b6
b7C

calls. was agreeable to conclude the interview at a future date.

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 05/30/2003

On May 29, 2003, [redacted] date of birth [redacted]
[redacted] Social Security Account Number [redacted] was
interviewed at [redacted] place of employment, [redacted]
[redacted] telephone [redacted] by Special
Agents (SAs) [redacted] After being
advised of the identities of the interviewing Agents and the
purpose of the interview, [redacted] provided the following
information:

b6
b7C

[redacted] earned a [redacted] degree in [redacted]
[redacted] UNIVERSITY in [redacted] and immediately began
working at [redacted]
initial work involved materials research and during [redacted] tenure at
[redacted] earned a [redacted] degree in [redacted]

In [redacted] assisted with the [redacted]
[redacted]
[redacted] began interacting
with the UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF
INFECTIOUS DISEASES (USAMRIID) in [redacted] USAMRIID personnel supplied
biological agents used for development and testing [redacted]
[redacted] was the main point of contact at USAMRIID and
[redacted]

[redacted] completed USAMRIID'S immunization
program and worked in room [redacted] of Building [redacted]
recalled that initial work was conducted [redacted]
[redacted] Sample handling and preparation were not conducted
in a biosafety containment suite, as the biological agents used in
testing, such as [redacted] were not
"hot". [redacted] provided and handled these materials

b6
b7C

Investigation on 05/29/2003 at [redacted]

File # 279A-WF-222936-USAMRIID, 279A-BA-C101392 Date dictated [redacted]

by SA [redacted]
SA [redacted]

b2
b7E

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of [REDACTED], On 05/29/2003, Page 2

and stored them in an upright, glass-door refrigerator in room [REDACTED]. On occasion, [REDACTED] would pipet small volumes of liquid material from vials onto [REDACTED]. After use, all samples and materials were decontaminated, either chemically or in the autoclave. [REDACTED] primary function was [REDACTED]. [REDACTED] maintained a variable on-site schedule, working at USAMRIID one day a week, or less.

b6
b7C
b2
b7F

While [REDACTED] was employed with [REDACTED]

[REDACTED]

b6
b7C

During [REDACTED] completed the immunization program and became [REDACTED] scientist for the sample handling aspects of the [REDACTED]

b6
b7C
b2
b7F

[REDACTED] Collaboration [REDACTED] interacted with [REDACTED] develop and refine a technique for [REDACTED]

[REDACTED] work was conducted with *Bacillus anthracis* (B.a.) Ames. The B.a. Ames spores were supplied in liquid form by BRUCE IVINS of USAMRIID and were stored in a refrigerator in room [REDACTED] of Building [REDACTED] with the assistance of [REDACTED] used a hood line in room [REDACTED]

[REDACTED] assisted [REDACTED]

[REDACTED] work on the project as [REDACTED]

b6
b7C

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of [REDACTED], On 05/29/2003, Page 3

b6
b7C
b2
b7F

[REDACTED]

[REDACTED] foremost responsibility was [REDACTED]

[REDACTED] The majority of [REDACTED] work [REDACTED]
containing captured *B.a.* Ames spores was conducted during [REDACTED]
[REDACTED] time frame. [REDACTED]

handled [REDACTED] but not the raw *B.a.* Ames spore material. [REDACTED] recalled holding the container of *B.a.* spores and looking at the material in the biosafety hood on one occasion. Prior to [REDACTED] *B.a.* Ames spores were stored on a small shelf in the room [REDACTED] walk-in cooler. [REDACTED] accessed this walk-in refrigerator in Building [REDACTED] and indicated that the area was packed with various materials. [REDACTED] recalled seeing racks of tubes and plastic boxes with lids; however, [REDACTED] did not look around too much. Once analyzed in [REDACTED]
[REDACTED] bleached to chemically deactivate the spores.

[REDACTED] worked at USAMRIID initially as a

[REDACTED]

b6
b7C

access to the [REDACTED] suites. The biocabinet housing [REDACTED] was shared with [REDACTED] however, the work conducted by [REDACTED] at USAMRIID was not related to [REDACTED] hands-on work in the laboratory was sporadic, as [REDACTED] primary function was that of [REDACTED] did not know the specifics of the research conducted by [REDACTED] indicated that [REDACTED] current studies involve collaboration with USAMRIID personnel.

[REDACTED]

The [REDACTED] using *B.a.* Ames were completed and the project was scheduled to continue using additional biological agents. [REDACTED] anticipated the set-up of this [REDACTED] at USAMRIID within the month. The project has been dormant of late, however, as

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of _____, On 05/29/2003, Page 4

_____ believed that the project will proceed as funding, _____ has been provided to USAMRIID for continued contributions to the project. _____ will supposedly replace _____ will continue to provide the _____ expressed doubts as to the feasibility of this arrangement.

_____ identified all of _____ work areas at USAMRIID on a floor plan provided by the Agents. The floor plan shown to _____ is maintained in a 1A envelope (FD-340). _____ was in USAMRIID Building _____ to access the _____ but _____ did not conduct laboratory work in this building.

_____ has never meet _____ heard _____
Aside from _____ and USAMRIID personnel directly involved in the _____ did not interact with USAMRIID employees. _____ recalled seeing _____ and individuals working in neighboring laboratory spaces.

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 05/09/2003

On May 8, 2003, [redacted] date of birth [redacted]
[redacted] Social Security Account Number [redacted] was
interviewed at [redacted] place of employment, [redacted]

b6
b7C

[redacted] by Special Agents (SAs) [redacted]
[redacted] After being advised of the identities of the Agents, [redacted]
provided the following information:

[redacted] has been working at [redacted]
[redacted] for approximately [redacted] Prior to [redacted] was a

[redacted] When the project was initiated, [redacted] was
the [redacted] Funding was
provided by [redacted] as the original [redacted]
[redacted] wanted to extend the study to the analysis of real
[redacted] rather than just simulants; thus, [redacted] contacted [redacted]
at the ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES
(USAMRIID). [redacted] funded USAMRIID'S contributions to the project,
as [redacted] could not provide funding to the military. A Memorandum of
Understanding was drafted between [redacted] and USAMRIID designating
the Institute as the provider of biological agents for use in
developing [redacted]

[redacted]
[redacted] to conduct studies at USAMRIID for the project. They
completed the vaccination series and began to work with [redacted]
[redacted] Multiple biological agents were
used in the studies, including [redacted] and *Bacillus*
anthracis (B.a.). [redacted] both with [redacted]
[redacted] backgrounds, did not grow any of the biological agents
for the studies.

[redacted] was hired by USAMRIID at
[redacted] prompting to assist [redacted] with the project. [redacted] had
the background necessary to [redacted] and may have supplied

Investigation on 05/08/2003 at [redacted]

File # 279A-WF-222936-USAMRIID. 279A-BA-C101392 Date dictated _____

by SA [redacted]
SA [redacted]

b6
b7C

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of _____, On 05/08/2003, Page 2

b6
b7C

biological samples internally to personnel at USAMRIID. [] did not grow [] used in the studies, rather [] interfaced with a person growing the virus in [] group at USAMRIID. [] received samples from [] who assisted significantly with sample handling. [] also [] for use in the project.

In addition to supplying [] samples for the project, [] provided training to [] laboratory protocols in a [] received initial [] training from [] of USAMRIID. [] spent no more than 40 hours in the [] spent a little more time than []

Initially, a commercial mass spectrometer was used to obtain the biological signatures of myriad agents. An organism in liquid form was deposited on a slide. Once dry, the slide was inserted into the instrument sample compartment for analysis. These measurements were made in [] laboratory space.

Extension of the project, to include [] required the construction of a [] Once [] was taken to USAMRIID for testing. [] laboratory was used to conduct the aerosol work. [] group worked with [] laboratory personnel, mainly [] Agents were []

[] worked mainly with *Bacillus anthracis*. BRUCE IVINS provided [] with a tube of liquid *B.a.* Ames spores at a concentration of $\sim 10^{12}$ cfu/mL. [] did not know the specifics of how the spores were grown, but recalled that the material was gradient purified using renograph. No additives were used to enhance the properties of the spores. The Ames spore preparation was stored in the [] walk-in cooler in the containment facility of Building [] The tape samples containing deposited agents were stored in a Tupperware container in the same location. [] did not recall the maintenance of a log or inventory for the walk-in cooler. [] was aware of the location and types of

b6
b7C
b2
b7F

279A-WF-222936-USAMRIID, 279A-BA-C101392

b6
b7C

Continuation of FD-302 of [REDACTED], On 05/08/2003, Page 3

samples [REDACTED] group was storing. [REDACTED] did not know what other materials were stored in the cooler. The cooler was accessible to anyone with authorization to enter the hot area of Building [REDACTED]

b6
b7C
b2
b7F

The tapes containing biological agents were autoclaved and discarded after use. A total of ~50 sample tapes were made for the project. [REDACTED] was designated as the caretaker of the remaining B.a. Ames spores when [REDACTED] left USAMRIID.

[REDACTED] conducted very limited work with the B.a. Ames, aside from [REDACTED] assisted with a [REDACTED]

b6
b7C

[REDACTED] has never met [REDACTED] did not hang around USAMRIID outside of [REDACTED] laboratory work and knew [REDACTED] individuals at the Institute, including [REDACTED]

[REDACTED] could not recall [REDACTED] response. [REDACTED] did not attend any [REDACTED]

[REDACTED] did not meet [REDACTED] at USAMRIID. [REDACTED]

[REDACTED] did not recall discussions with [REDACTED] regarding what countries had weaponized anthrax. Medical and environmental biological samples may have been discussed, as scientists often culture isolates from dead animals to obtain diverse strains for assay development.

[REDACTED] did not believe, for several reasons, that the anthrax mailings were performed by a terrorist organization. The mailer did not capitalize on the advantage gained after the first mailings by sending additional letters. The odd pattern indicated to [REDACTED] that the mailer ran out of agent, which would be unlikely for a terrorist group capable of manufacturing a large amount of material.

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of [REDACTED], On 05/08/2003, Page 4

b6
b7C

[REDACTED] prior to working with [REDACTED] at USAMRIID. [REDACTED] left USAMRIID for a job at the [REDACTED] has worked at the [REDACTED] for approximately [REDACTED] one or two people formerly at USAMRIID, [REDACTED]

[REDACTED] has continued to work at [REDACTED]
[REDACTED] will be taken to USAMRIID for studies using biological agents. [REDACTED] will use the same B.a. Ames spore preparation used initially by [REDACTED]
[REDACTED] trained personnel will also help run the samples.

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 07/28/2003

[redacted] date of birth [redacted]
[redacted] social security number [redacted] home
address [redacted] home
telephone number [redacted] was interviewed at [redacted] place of
employment, the United States Army Medical Research Institute of
Infectious Diseases (USAMRIID), Fort Detrick, Maryland, work
telephone number [redacted] After being advised of the
identities of the interviewing agents and the purpose of the
interview, [redacted] provided the following information:

b6
b7C

[redacted] and has been
employed at USAMRIID since [redacted] received a degree
[redacted] University.

[redacted]
[redacted] work at USAMRIID is
mostly conducted in the [redacted] gained suite access in
[redacted] also has access to the hot suites and [redacted] has
participated in aerosol challenges. [redacted] was not positive if [redacted]
ever handled Bacillus anthracis (BA). [redacted] stated the last time
[redacted] believed [redacted] handled anthrax was in [redacted]
received a pipet of a solution from BRUCE IVINS which [redacted] spread on
agar plates. [redacted] believed the solutions were anthrax and does
not know the type of strain.

[redacted] does not maintain a diary or log concerning [redacted]
work. [redacted] does not use a lyophilizer and has never dried
anthrax. [redacted] does not use sterilite containers and does not
recall seeing these type of containers at USAMRIID. [redacted] does
not know where anthrax is stored but guessed it would be in the [redacted]
suite. [redacted] does not know of anyone who could be associated with
the anthrax mailings.

b6
b7C
b2
b7F

[redacted] uses the walk in cooler on the [redacted] near
[redacted] in building [redacted] to store vials of serum. [redacted]
never witnessed anyone " piggy back" in and out of the hot/suites,
and could not recall if [redacted] had ever saw foreign visitors enter the
hot suites.

b6
b7C

July 25, 2003 Fort Detrick, Maryland [redacted] 302

Investigation on [redacted] at [redacted]

65-1279A-WF-222936USAMRIID 279A-WF-222936 [redacted] 302-914

File # 279A-BA-C101392 - 125

Date dictated July 27, 2003

by U.S. POSTAL INSPECTOR [redacted]
U.S. POSTAL INSPECTOR [redacted]

b2
b7E

279A-WF-222936USAMRIID 279A-WF-222936-[] 302
279-BA-C101392

Continuation of FD-302 of [] , On July 25, 2002, Page 2

b6
b7C

[] has not been contacted by anyone trying to obtain anthrax or anything else from USAMRIID. [] does not use or purchase pre-stamped envelopes and has not/seen any at USAMRIID.

[] does not personally know [] and has never met [] never saw [] at USAMRIID.

[] has no friends or associates who reside in New Jersey. [] believes [] during the dates of the anthrax mailings. [] provided agents copies of [] employee time sheets records.

Copies of [] time sheet records are enclosed in a 1A envelope.

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 07/24/2003

On July 22, 2003, SA [] and SA []
[] interviewed [] date of birth []
social security account number [] at [] place of
employment, the United States Army Medical Research Institute of
Infectious Diseases (USAMRIID), located at [] Porter Street, Fort
Detrick, Maryland, telephone [] where [] works as a
[]
[] After being
advised of the identity of the agents and the purpose of the
interview, [] provided the following information:

b6
b7C

[] was on []
[] at which time [] left []
[]

b6
b7C

[] primary work areas are Suites [] and []
also works in Suite [] Rooms [] and Building
[] Rooms []
frequently. [] does some work for []
[]

b6
b7C

[] wears gloves the entire time that [] is in a hot
suite, with the exception of when [] is in the office area and when
[] uses the telephone. [] only wears gloves in a cold laboratory
when [] is using sterile technique or when [] is working inside of
a hood.

b6
b7C

Some piggyback entry occurs through doorways around
USAMRIID, however it has decreased within the last two years.
There is not any piggyback entry into hot suites. [] knew of
one exception to this wherein a person who was in training and did

Investigation on 07/22/2003 at Fort Detrick, Maryland

167 279A-WF-222936- [] 302-916 1187
File # 279A-WF-222936-USAMRIID/279A-BA-C101392 Date dictated N/A

b6
b7C

SA []
by SA []

b6
b7C

[redacted] did not work with or handle the letter, envelope or material contained therein from the Daschle, Leahy, New York Post, or Brokaw mailings. [redacted] only knowledge of any work done with the letters is as follows.

b6
b7C
b2
b7E

[redacted] advised that the airlock on the [redacted] of Building [redacted] is not meant to be used as an entry for people. If a person was to enter the hot side through any door other than the change rooms, an alarm would ring. If one of the two doors leading to the airlock is open, the other door cannot be open at the same time. The [redacted] passbox is located on the [redacted] of the building.

[redacted] has worked all strains of *Bacillus anthracis* (B.a.) that IVINS maintains including Vollum 1B and Texas. [redacted]
[redacted] *Bacillus anthracis* (B.a.) Ames spores for use in aerosol studies and has used B.a. Ames in injection studies as well. [redacted] has also done anthrax [redacted] studies with

b6
b7C

BASSETT grows [] own B.a. Ames spores using the Leighton-Doi method. The only incubator that he has ever used for this purpose is located in Room [] [] obtained [] original B.a. Ames stock from a 1998 IVINS stock solution.

b6
b7C
b2
b7E

[redacted] in the -70 degree Celsius freezer located in the Suite [redacted] hallway, and in the refrigerator in Room [redacted] and a freezer log

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of [REDACTED], On 07/22/2003, Page 4

is maintained which contains such information as who the material belongs to and where it originated from.

b6
b7C

[REDACTED] autoclaves any extra *B.a.* Ames spores on the same day of the study in which it was used, with the exception of when the autoclave is down for maintenance. [REDACTED] has never shared any *B.a.* Ames spore preparations. [REDACTED]

[REDACTED] has never worked with [REDACTED] and [REDACTED] had no knowledge of a mock dry *B.a.* Ames experiment [REDACTED] stored media plates in the Room [REDACTED] cold room, and never saw any *B.a.* Ames stored in there. [REDACTED] never saw [REDACTED] near Room [REDACTED]

b6
b7C
b2
b7F

- 1 -

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 05/16/2003

On May 13, 2003, [redacted] date of birth [redacted] social security account number [redacted] was interviewed at [redacted] place of employment, the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), [redacted] Porter Street, Fort Detrick, Maryland, telephone [redacted]. After being advised of the identity of the agents and the purpose of the interview, [redacted] provided the following information:

b6
b7C

In addition to [redacted] created for SA [redacted] Baltimore FBI; [redacted] [redacted] agreed to locate a copy of the [redacted] for the agents.

b6
b7C

[redacted] worked in some capacity with [redacted] [redacted] recollection of [redacted] work with the [redacted] the individuals present, and [redacted]

[redacted] had limited contact with [redacted] [redacted] was not present for the [redacted]

b6
b7C
b2
b7E

[redacted] advised that USAMRIID received very little material from the Brokaw letter, only two to three "grains". The New York FBI office first sent the letter to the Centers for Disease Control (CDC), and the FBI then moved the letter from the CDC to USAMRIID. USAMRIID was advised not to do any work with the letter until given further notice, and it was stored at room temperature in Room [redacted] in a locked cabinet. [redacted] thinks

b2
b7E

Investigation on 05/13/2003 at Fort Detrick, Maryland
File # 279A-WF-222936-302-3130 1153
279A-WF-222936-USAMRIID/279A-BA-C101392 Date dictated N/A
by SA [redacted]

b6
b7C

279A-WF-222936-USAMRIID, 279A-BA-C101392

Continuation of FD-302 of [REDACTED], On 05/13/2003, Page 2

b6
b7C

that one "grain" of the B.a. was removed and sent for EM. A swab of the envelope was taken for culture purposes.

USAMRIID held the Leahy letter in storage and did not do any work with it for an extended period of time. The letter remained in the original plastic can in which it was received, with the evidence tape still intact. During this time, there were numerous meetings about how the letter should be handled, and a protocol was written outlining the exact steps to be taken. In addition, a room in Suite [REDACTED] was being set up to work the Leahy letter in accordance with the established protocol.

b6
b7C
b2
b7F

[REDACTED] was moved into Suite [REDACTED] to be used for work with the Leahy letter. This [REDACTED]

[REDACTED] volunteered the use of [REDACTED] in response to a canvass of USAMRIID requesting one.

[REDACTED]

[REDACTED]

From the time the Leahy letter was opened, the two person team rule was put into effect from that point forward. Once the doors to Rooms [REDACTED] were double secured, the stored letters were moved there from Room [REDACTED].